BioCentury
ARTICLE | Financial News

Tekmira planning follow-on

October 17, 2013 12:03 AM UTC

RNAi company Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) proposed a follow-on late Wednesday underwritten by Stifel and Maxim Group. Tekmira's lead internal candidate is TKM-PLK1, which is in Phase I/II testing to treat advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma, with data expected in mid-2014. TKM-PLK1 comprises short interfering RNA (siRNA) targeting polo-like kinase 1 (PLK1; STPK13) formulated with the company's lipid nanoparticle (LNP) technology. ...